Therapeutically active compounds and their methods of use
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
1. A method of treating myelodysplastic syndrome (MDS) characterized by having an IDH1 mutation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide:
or a pharmaceutically acceptable salt or hydrate thereof.
2. The method of claim 1 wherein the IDH1 mutation is an IDH1 R132X mutation.
3. The method of claim 1 wherein the IDH1 mutation is an R132H or R132C mutation.